Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Leuk Lymphoma. 2021 Apr 11;62(5):1167–1177. doi: 10.1080/10428194.2021.1910684

Figure 4. Ruxolitinib and venetoclax single agent and combination treatment is not efficacious against T-ALL in vivo.

Figure 4.

(A) Schematic of experimental design. (B-C) Clinical score (B) and percent survival (C) of single agent ruxolitinib, venetoclax or combination treatment given by oral gavage once daily for 14 days starting at seven days post Jurkat transplant. N=5 mice/group.